Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMVT NASDAQ:KYMR NASDAQ:LNTH NASDAQ:SNDX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMVTImmunovant$31.15+0.7%$28.20$14.32▼$36.28$6.35B0.762.52 million shs1.90 million shsKYMRKymera Therapeutics$73.18+2.6%$83.10$36.65▼$103.00$5.86B2.02467,089 shs860,564 shsLNTHLantheus$100.25+4.1%$86.93$47.25▼$103.89$6.27B-0.031.15 million shs1.08 million shsSNDXSyndax Pharmaceuticals$18.34-0.3%$21.90$8.59▼$25.59$1.63B0.381.32 million shs1.25 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMVTImmunovant-5.90%-8.60%+14.01%+14.18%+100.65%KYMRKymera Therapeutics-9.15%-11.74%-11.67%-17.21%+65.29%LNTHLantheus-0.85%-3.76%+12.63%+23.72%+24.85%SNDXSyndax Pharmaceuticals-2.44%-7.59%-3.62%-14.94%+67.49%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMVTImmunovant$31.15+0.7%$28.20$14.32▼$36.28$6.35B0.762.52 million shs1.90 million shsKYMRKymera Therapeutics$73.18+2.6%$83.10$36.65▼$103.00$5.86B2.02467,089 shs860,564 shsLNTHLantheus$100.25+4.1%$86.93$47.25▼$103.89$6.27B-0.031.15 million shs1.08 million shsSNDXSyndax Pharmaceuticals$18.34-0.3%$21.90$8.59▼$25.59$1.63B0.381.32 million shs1.25 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMVTImmunovant-5.90%-8.60%+14.01%+14.18%+100.65%KYMRKymera Therapeutics-9.15%-11.74%-11.67%-17.21%+65.29%LNTHLantheus-0.85%-3.76%+12.63%+23.72%+24.85%SNDXSyndax Pharmaceuticals-2.44%-7.59%-3.62%-14.94%+67.49%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMVTImmunovant 2.45Hold$37.3319.85% UpsideKYMRKymera Therapeutics 2.95Moderate Buy$118.1061.38% UpsideLNTHLantheus 2.73Moderate Buy$101.861.60% UpsideSNDXSyndax Pharmaceuticals 2.92Moderate Buy$42.55131.98% UpsideCurrent Analyst Ratings BreakdownLatest SNDX, IMVT, KYMR, and LNTH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2026SNDXSyndax Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$40.005/27/2026LNTHLantheus MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$100.00 ➝ $115.005/26/2026LNTHLantheus Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)5/26/2026IMVTImmunovant GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$44.00 ➝ $62.005/22/2026IMVTImmunovant Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$23.00 ➝ $30.005/22/2026SNDXSyndax Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$40.005/21/2026IMVTImmunovant CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/21/2026IMVTImmunovant HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$35.00 ➝ $40.005/21/2026IMVTImmunovant Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$32.00 ➝ $43.005/13/2026SNDXSyndax Pharmaceuticals UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$38.00 ➝ $37.005/11/2026LNTHLantheus Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$98.00 ➝ $115.00(Data available from 6/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMVTImmunovantN/AN/AN/AN/A$4.19 per shareN/AKYMRKymera Therapeutics$39.21M153.52N/AN/A$19.42 per share3.77LNTHLantheus$1.54B4.23$6.59 per share15.21$16.43 per share6.10SNDXSyndax Pharmaceuticals$172.35M9.43N/AN/A$0.74 per share24.78Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMVTImmunovant-$505.61M-$2.78N/AN/AN/AN/A-65.66%-59.88%8/10/2026 (Estimated)KYMRKymera Therapeutics-$311.35M-$3.57N/AN/AN/A-611.94%-24.71%-22.05%8/10/2026 (Estimated)LNTHLantheus$233.56M$4.1524.1618.67N/A18.05%29.32%15.00%8/5/2026 (Estimated)SNDXSyndax Pharmaceuticals-$285.42M-$2.79N/AN/AN/A-111.88%-256.65%-45.25%8/3/2026 (Estimated)Latest SNDX, IMVT, KYMR, and LNTH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2026Q4 2026IMVTImmunovant-$0.60-$0.73-$0.13-$0.73N/AN/A5/7/2026Q1 2026LNTHLantheus$1.25$1.46+$0.21$1.80$354.48 million$377.33 million4/30/2026Q1 2026KYMRKymera Therapeutics-$0.89-$0.71+$0.18-$0.71$8.27 million$34.37 million4/30/2026Q1 2026SNDXSyndax Pharmaceuticals-$0.59-$0.48+$0.11-$0.48$69.76 million$64.86 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthIMVTImmunovantN/AN/AN/AN/AN/AKYMRKymera TherapeuticsN/AN/AN/AN/AN/ALNTHLantheusN/AN/AN/AN/AN/ASNDXSyndax PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMVTImmunovantN/A9.099.09KYMRKymera TherapeuticsN/A10.8110.81LNTHLantheus0.472.832.64SNDXSyndax Pharmaceuticals8.265.475.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMVTImmunovant47.08%KYMRKymera TherapeuticsN/ALNTHLantheus99.06%SNDXSyndax PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipIMVTImmunovant1.80%KYMRKymera Therapeutics15.98%LNTHLantheus1.70%SNDXSyndax Pharmaceuticals4.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMVTImmunovant120205.31 million201.61 millionOptionableKYMRKymera Therapeutics17082.26 million69.11 millionOptionableLNTHLantheus1,19365.11 million64.00 millionOptionableSNDXSyndax Pharmaceuticals11088.61 million84.98 millionOptionableSNDX, IMVT, KYMR, and LNTH HeadlinesRecent News About These CompaniesSyndax Pharmaceuticals (NASDAQ:SNDX) CFO Keith Goldan Sells 1,177 SharesJune 3 at 6:44 AM | insidertrades.comSyndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant DataJune 2 at 4:01 PM | globenewswire.comSyndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026June 1 at 7:00 AM | globenewswire.comAssessing Whether Syndax Pharmaceuticals (SNDX) Looks Undervalued After Recent Share Price WeaknessMay 24, 2026 | finance.yahoo.comSyndax Pharmaceuticals (NASDAQ:SNDX) Given Buy Rating at HC WainwrightMay 23, 2026 | americanbankingnews.comSyndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant DataMay 21, 2026 | globenewswire.comSyndax Announces Participation in Upcoming Investor ConferencesMay 20, 2026 | globenewswire.comSyndax Pharmaceuticals Inc SNDXMay 19, 2026 | morningstar.comMWhy Syndax Pharmaceuticals (SNDX) is One of the Best Small Cap Stocks to Buy for 10x PotentialMay 14, 2026 | insidermonkey.comSyndax Highlights 12 Revuforj® (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin InhibitionMay 12, 2026 | globenewswire.comSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)May 6, 2026 | globenewswire.comSyndax Pharmaceuticals, Inc. 2026 Q1 - Results - Earnings Call PresentationMay 5, 2026 | seekingalpha.comBiotech Momentum Builds As Syndax Pharmaceuticals Draws Market AttentionMay 5, 2026 | kalkinemedia.comKBank of America Securities Reaffirms Their Buy Rating on Syndax Pharmaceuticals (SNDX)May 5, 2026 | theglobeandmail.comHC Wainwright Has Optimistic Outlook of SNDX Q2 EarningsMay 5, 2026 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Up 6.6% Following Analyst UpgradeMay 4, 2026 | marketbeat.comHC Wainwright Has Optimistic Outlook of SNDX FY2030 EarningsMay 4, 2026 | marketbeat.comSyndax Slide Puts Nasdaq Index Biotech in FocusMay 2, 2026 | kalkinemedia.comKSyndax Pharmaceuticals Inc (SNDX) Q1 2026 Earnings Call Highlights: Record Revenue Growth and ...May 2, 2026 | finance.yahoo.comSyndax (SNDX) Narrows Losses as Revuforj and Niktimvo Gain Traction - What’s Really Shifting?May 2, 2026 | finance.yahoo.comSyndax: Q1 Earnings SnapshotApril 30, 2026 | stamfordadvocate.comSNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSNDX, IMVT, KYMR, and LNTH Company DescriptionsImmunovant NASDAQ:IMVT$31.15 +0.23 (+0.74%) Closing price 04:00 PM EasternExtended Trading$31.12 -0.02 (-0.08%) As of 06:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.Kymera Therapeutics NASDAQ:KYMR$73.18 +1.89 (+2.65%) Closing price 03:58 PM EasternExtended Trading$73.17 -0.01 (-0.01%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Lantheus NASDAQ:LNTH$100.25 +3.95 (+4.10%) Closing price 04:00 PM EasternExtended Trading$100.18 -0.08 (-0.07%) As of 06:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.Syndax Pharmaceuticals NASDAQ:SNDX$18.34 -0.05 (-0.27%) As of 04:00 PM EasternSyndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Coke's $10B India IPO Plan Pops the Top on Hidden Value Palo Alto Networks Accelerates Growth 31% on AI Demand Motorola's $1.5B Bet to Own the Skies Microsoft Build 2026 Is Really Just One Big AI Stress Test FedEx Unboxes Billions in Post-Spinoff Value Slice of the Pie: Why Yum’s Deal Lifts QSR Urban Outfitters Stock Stalls Despite Another Strong Quarter What IBM's $10-Billion Quantum Project Means For Smaller Players Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
